NCT07651475Active, not recruitingPhase 2
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
An Exploratory Clinical Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia for Prospective, Single-arm, Phase II
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
The purpose of this study is to determine the efficacy and safety of the Beach regimen on relapsed/refractory acute myeloid leukemia
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 32 (estimated)
- First submitted
- 11 Jun 2026
- Start date
- 30 Jul 2026
- Primary completion date
- 31 Mar 2027
- Lead sponsor
- Liping Dou
- Diseases
- Acute myeloid leukemia
- NCT number
- NCT07651475
What you commit to
- Study type: Interventional · Phase 2
- Planned participants: 32
- From 30 Jul 2026 to the primary completion date, 31 Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior treatment with EZH1/2 inhibitors
- Allogeneic hematopoietic stem cell transplantation within 6 months
- Undergone major organ surgery within the previous 6 weeks and whose recovery was not complete
Other illness
- Hypersensitivity to any study drug
- Dysphagia or uncontrolled gastrointestinal disease impairing oral intake
- Severe chronic respiratory disease requiring continuous oxygen
- Clinically significant cardiac, renal, hepatic, neurologic, or endocrine disease; Child-Pugh B/C cirrhosis
- Active uncontrolled infection including HBV, HCV, HIV, syphilis
Other
- Acute promyelocytic leukemia (APL)
- Participation in another interventional trial within 4 weeks
- Smoking and excessive drinking have affected the evaluation of the test results;
- Pregnant or breastfeeding women; women planning pregnancy during study
- The patients deemed unsuitable by the researchers to participate in this study. -
Who the study is looking for
- Age 18-75 years
- Confirmed diagnosis of R/R AML
- Adequate organ function: TBIL ≤2×ULN; ALT/AST ≤2.5×ULN; Cr ≤ULN or Ccr ≥50 mL/min
- ECOG performance status ≤2
- Life expectancy ≥4 months
- No severe allergic history
- Not participating in other interventional trials during study
- Signed informed consent -
Age in the registry: 18 years to 75 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Chinese PLA General Hospital Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.